波多野 正和

Medicine & Life Sciences

1. Antipsychotic Agents 100%
2. Schizophrenia 80%
3. Aripiprazole 64%
4. Bipolar Disorder 52%
5. Injections 48%
6. Lithium 41%
7. Systematic Reviews 40%
8. Placebos 38%
9. Asenapine 37%
10. Network Meta-Analysis 36%
11. Olanzapine 35%
12. Meta-Analysis 34%
13. Propensity Score 32%
14. Randomized Controlled Trials 29%
15. Recurrence 25%
16. suvorexant 24%
17. Polypharmacy 22%
18. Quetiapine Fumarate 22%
19. Odds Ratio 21%
20. Retrospective Studies 21%
21. Risperidone 20%
22. Maintenance 20%
23. Deltoid Muscle 19%
24. Vortioxetine 19%
25. Desvenlafaxine Succinate 19%
26. Therapeutics 19%
27. Nivolumab 18%
28. Paliperidone Palmitate 17%
29. Lamotrigine 17%
30. Febrile Neutropenia 17%
31. Drug-Related Side Effects and Adverse Reactions 16%
32. Nephritis 16%
33. Japan 16%
34. Proton Pump Inhibitors 15%
35. Lansoprazole 15%
36. Venlafaxine Hydrochloride 15%
37. Sertraline 15%
38. cariprazine 14%
39. GABA-A Receptors 14%
40. ziprasidone 14%
41. Sleep Initiation and Maintenance Disorders 14%
42. Major Depressive Disorder 14%
43. Databases 13%
44. Pharmacists 13%
45. Confidence Intervals 13%
46. Fluorouracil 13%
47. Safety 12%
48. Carbamazepine 12%
49. Rabeprazole 12%
50. Cisplatin 12%